Tags

Type your tag names separated by a space and hit enter

Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Clin Infect Dis. 2011 May; 52(9):1156-63.CI

Abstract

Ceftaroline (PPI 0903, formerly TAK-599), the active metabolite of a N-phosphono prodrug, ceftaroline fosamil, has been approved by the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. This antimicrobial agent binds to penicillin binding proteins (PBP) inhibiting cell wall synthesis and has a high affinity for PBP2a, which is associated with methicillin resistance. Ceftaroline is consistently active against multidrug-resistant Streptococcus pneumoniae and Staphylococcus aureus, including methicillin-resistant, vancomycin-intermediate, linezolid-resistant, and daptomycin-nonsusceptible strains. It possesses variable activity against Enterobacteriaceae and good activity against oral anaerobes. The drug is usually administrated intravenously at 600 mg every 12 h. Ceftaroline has low protein binding and is excreted by the kidneys and thus requires dose adjustments in individuals with renal failure. Clinical trials have demonstrated noninferiority when compared with vancomycin in the treatment of acute bacterial skin and skin structure infections and noninferiority when compared with ceftriaxone in the treatment of community-acquired bacterial pneumonia. Ceftaroline demonstrated a safety profile similar to that of comparator drugs in clinical trials.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Saravolatz LD
Department of medicine, St John Hospital and Medical Center, Wayne State University School of Medicine, East Lansing, Michigan, USA. louis.saravolatz@stjohn.org
Stein GE
No affiliation info available
Johnson LB
No affiliation info available

MeSH

AdultAnimalsAnti-Bacterial AgentsCephalosporinsClinical Trials as TopicCommunity-Acquired InfectionsFemaleHumansMaleMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMiddle AgedPneumonia, BacterialRabbitsStaphylococcal InfectionsStreptococcus pneumoniae

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21467022

Citation

Saravolatz, Louis D., et al. "Ceftaroline: a Novel Cephalosporin With Activity Against Methicillin-resistant Staphylococcus Aureus." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 52, no. 9, 2011, pp. 1156-63.
Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011;52(9):1156-63.
Saravolatz, L. D., Stein, G. E., & Johnson, L. B. (2011). Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 52(9), 1156-63. https://doi.org/10.1093/cid/cir147
Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a Novel Cephalosporin With Activity Against Methicillin-resistant Staphylococcus Aureus. Clin Infect Dis. 2011;52(9):1156-63. PubMed PMID: 21467022.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. AU - Saravolatz,Louis D, AU - Stein,Gary E, AU - Johnson,Leonard B, PY - 2011/4/7/entrez PY - 2011/4/7/pubmed PY - 2011/8/16/medline SP - 1156 EP - 63 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 52 IS - 9 N2 - Ceftaroline (PPI 0903, formerly TAK-599), the active metabolite of a N-phosphono prodrug, ceftaroline fosamil, has been approved by the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. This antimicrobial agent binds to penicillin binding proteins (PBP) inhibiting cell wall synthesis and has a high affinity for PBP2a, which is associated with methicillin resistance. Ceftaroline is consistently active against multidrug-resistant Streptococcus pneumoniae and Staphylococcus aureus, including methicillin-resistant, vancomycin-intermediate, linezolid-resistant, and daptomycin-nonsusceptible strains. It possesses variable activity against Enterobacteriaceae and good activity against oral anaerobes. The drug is usually administrated intravenously at 600 mg every 12 h. Ceftaroline has low protein binding and is excreted by the kidneys and thus requires dose adjustments in individuals with renal failure. Clinical trials have demonstrated noninferiority when compared with vancomycin in the treatment of acute bacterial skin and skin structure infections and noninferiority when compared with ceftriaxone in the treatment of community-acquired bacterial pneumonia. Ceftaroline demonstrated a safety profile similar to that of comparator drugs in clinical trials. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/21467022/Ceftaroline:_a_novel_cephalosporin_with_activity_against_methicillin_resistant_Staphylococcus_aureus_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cir147 DB - PRIME DP - Unbound Medicine ER -